Adaptive inhibitors of the HIV-1 protease

Progress in Biophysics and Molecular Biology

Volumn 88, Issue 2, 2005, Pages 193-208

  Ohtaka, Hiroyasu ^a   Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adaptive inhibitors; Binding enthalpy; Binding thermodynamics; Drug design; Drug resistance; Isothermal titration calorimetry

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTATION; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; METHODOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 9644257332     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2004.07.005     Document Type: Review

References (41)

1. P.J. Ala, E.E. Huston, R.M. Klabe, D.D. McCabe, J.L. Duke, C.J. Rizzo, B.D. Korant, R.D. DeLoskey, P.Y.S. Lam, C.N. Hodge, and C.H. Chang Molecular basis of HIV-1 protease drug resistance structural analysis of mutant proteases complexed with cyclic urea inhibitors Biochemistry 36 1997 1573 1580
2. D. Boden, and M. Markowitz Resistance to immunodeficiency virus type 1 protease inhibitors Antimicrob. Agents Chemother. 42 1998 2775 2783
3. S. Cabani, P. Gianni, V. Mollica, and L. Lepori Group contributions to the thermodynamic properties of non-ionic organic solutes in dilute aqueous solution J. Solution Chem. 10 1981 563 595
4. F. Cazein, F. Hamers, J. Alix, and J.B. Brunet Prevalence of HIV-2 infection in Europe Euro. Surveillance 1 1996 21 23
5. P. Colson, M. Henry, C. Tourres, D. Lozachmeur, H. Gallais, J.A. Gastaut, J. Moreau, and C. Tamalet Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France J. Clin. Microbiol. 42 2004 570 577
6. J.H. Condra, W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, J.C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K.E. Squires, P.J. Deutsch, and E.A. Emini In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374 1995 569 571
7. J.W. Erickson, and S.K. Burt Structural mechanisms of HIV drug resistance Annu. Rev. Pharmacol. Toxicol. 36 1996 545 571
8. E. Freire Designing drugs against heterogeneous targets Nat. Biotechnol. 20 2002 15 16
9. S. Gulnik, J.W. Erickson, and D. Xie HIV protease enzyme function and drug resistance G. Litwack Vitamins and Hormones 1999 Academic Press New York
10. K. Hertogs, S. Bloor, S.D. Kemp, C. Van den Eynde, T.M. Alcorn, R. Pauwels, M. Van Houtte, S. Staszewski, V. Miller, and B.A. Larder Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance a survey of over 6000 samples AIDS 14 2000 1203 1210
11. D.D. Ho, T. Toyoshima, H. Mo, D.J. Kempf, D. Norbeck, C. Chen, N.E. Wideburg, S.K. Burt, J.W. Erickson, and M.K. Singh Characterization of human immunodeficiency virus type 1 variants with increased resistant to a C2-symmetric protease inhibitor J. Virol. 68 1994 2016 2020
12. L. Hong, A. Treharne, J.A. Hartsuck, S. Foundling, and J. Tang Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases Biochemistry 35 1996 10627 10633
13. P.K. Jadhav, P. Ala, F.J. Woerner, C.H. Chang, and S.S. Garber Cyclic urea amides HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV J. Med. Chem. 40 1997 181 191
14. A.H. Kaplan, S.F. Michael, R.S. Wehbie, M.F. Knigge, D.A. Paul, L. Everitt, D.J. Kempf, D.W. Norbeck, and J.W. Erickson Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease Proc. Natl. Acad. Sci. USA 91 1994 5597 5601
15. M.J. Kozal, N. Shah, N. Shen, R. Yang, R. Fucini, T.C. Merigan, D.D. Richman, D. Morris, E. Hubbell, M. Chee, and T.R. Gingeras Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays Nat. Med. 2 1996 753 759
16. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249
17. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 23 1997 3 25
18. I. Luque, and E. Freire Structural parameterization of the binding enthalpy of small ligands Proteins 49 2002 181 190
19. I. Luque, M.J. Todd, J. Gomez, N. Semo, and E. Freire The molecular basis of resistance to HIV-1 protease inhibition a plausible hypothesis Biochemistry 37 1998 5791 5797
20. S. Muzammil, P. Ross, and E. Freire A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance Biochemistry 42 2003 631 638
21. H. Ohtaka, A. Velazquez-Campoy, D. Xie, and E. Freire Overcoming drug resistance in HIV-1 chemotherapy the binding thermodynamics of amprenavir and TMC-126 to wild type and drug-resistant mutants of the HIV-1 protease Protein Sci. 11 2002 1908 1916
22. H. Ohtaka, A. Schon, and E. Freire Multi drug-resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations Biochemistry 42 2003 13659 13666
23. D.B. Olsen, M.W. Stahlhut, C.A. Rutkowski, H.B. Schock, A.L. vanOlden, and L.C. Kuo Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors J. Biol. Chem. 274 1999 23699 23701
24. N.T. Parkin, and J.M. Schapiro Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV Antiviral Ther. 9 2004 3 12
25. J.D. Reeves, and R.W. Doms Human immunodeficiency virus type 2 J. Gen. Virol. 83 2002 1253 1265
26. N.A. Roberts Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors AIDS 9 1995 S27 S32
27. A. Schon, M. Ingaramo, and E. Freire The binding of HIV-1 protease inhibitors to human serum proteins Biophys. Chem. 105 2003 221 230
28. R.W. Shafer, T.K. Chuang, P. Hsu, C.B. White, and D.A. Katzenstein Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type I seroconverters in Zimbabwe AIDS Res. Human Retroviruses 15 1999 65 69
29. M.J. Todd, I. Luque, A. Velazquez-Campoy, and E. Freire The thermodynamic basis of resistance to HIV-1 protease inhibition. Calorimetric analysis of the V82F/I84V active site resistant mutant Biochemistry 39 2000 11876 11883
30. S. Vega, L.W. Kang, A. Velazquez-Campoy, Y. Kiso, L.M. Amzel, and E. Freire A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease Proteins 55 2004 594 602
31. A. Velazquez-Campoy, and E. Freire Incorporating target heterogeneity in drug design J. Cell. Biochem. S37 2001 82 88
32. A. Velazquez-Campoy, I. Luque, M.J. Todd, M. Milutinovich, Y. Kiso, and E. Freire Thermodynamic dissection of the binding energetics of KNI-272, a powerful HIV-1 protease inhibitor Protein Sci. 9 2000 1801 1809
33. A. Velazquez-Campoy, M.J. Todd, and E. Freire HIV-1 protease inhibitors enthalpic versus entropic optimization of the binding affinity Biochemistry 39 2000 2201 2207
34. A. Velazquez-Campoy, Y. Kiso, and E. Freire The binding energetics of first and second generation HIV-1 protease inhibitors implications for drug design Arch. Biochim. Biophys. 390 2001 169 175
35. A. Velazquez-Campoy, I. Luque, and E. Freire The application of thermodynamic methods in drug design Thermochim. Acta 380 2001 217 227
36. A. Velazquez-Campoy, I. Luque, and E. Freire The use of isothermal titration calorimetry in drug design applications to high affinity binding and protonation/deprotonation coupling Netsu Sokutei 28 2001 68 73
37. A. Velazquez-Campoy, M.J. Todd, S. Vega, and E. Freire Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes Proc. Natl. Acad. Sci. USA 98 2001 6062 6067
38. A. Velazquez-Campoy, S. Vega, and E. Freire Amplification of the effects of drug-resistance mutations by background polymorphisms in HIV-1 protease from African subtypes Biochemistry 41 2002 8613 8619
39. A. Velazquez-Campoy, S. Muzammil, H. Ohtaka, A. Schon, S. Vega, and E. Freire Structural and thermodynamic basis of resistance to HIV-1 protease inhibition implications for inhibitor design Curr. Drug Targets - Infect. Disorders 3 2003 311 328
40. A. Velazquez-Campoy, S. Vega, E. Fleming, U. Bacha, Y. Sayed, H.W. Dirr, and E. Freire Protease inhibition in African subtypes of HIV-1 AIDS Rev. 5 2003 165 171
41. T.D. Wu, C.A. Schiffer, M.J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A.R. Zolopa, W.J. Fessel, and R.W. Shafer Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments J. Virol. 77 2003 4836 4847